• 1

    Drake LA, Scher RK, Smith EB, et al: Effect of onychomycosis on quality of life. .J Am Acad Dermatol 38::702. ,1998. .

  • 2

    Baran R, Haneke E: “Fungal Nail Infection,” in Nail Surgery: A Text and Atlas, ed by EA Krull, EG Zook, R Baran, et al, p 183, Lippincott Williams & Wilkins, Philadelphia, 2001..

  • 3

    Gupta AK, Jain HC, Lynde CW, et al: Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada: a multicenter survey of 2001 patients. .Int J Dermatol 36::783. ,1997. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Elewski BE, Charif MA: Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. .Arch Dermatol 133::1172. ,1997. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Gupta AK: Management options in onychomycosis. .Am J Sports Med 2::117. ,2000. .

  • 6

    Roberts DT: Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. .Br J Dermatol 126::23. ,1992. .

  • 7

    Sais G, Juggla A, Peyri J: Prevalence of dermatophyte onychomycosis in Spain: a cross sectional study. .Br J Dermatol 132::758. ,1995. .

  • 8

    Denning DW, Evans EGV, Kibbler CC, et al: Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). .BMJ 311::1277. ,1995. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Elewski BE, Hay RJ: Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. .Clin Infect Dis 23::305. ,1996. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Midgley G, Moore MK, Cook JC, et al: Mycology of nail disorders. .J Am Acad Dermatol 31::S68. ,1994. .

  • 11

    Clayton YM: Clinical and mycological diagnostic aspects of onychomycosis and dermatomycosis. .Clin Exp Dermatol 17::37. ,1997. .

  • 12

    André J, Achten G: Onychomycosis. .Int J Dermatol 26::481. ,1987. .

  • 13

    Cohen JL, Scher RK, Pappert AS: “The Nail and Fungus Infections,” in Cutaneous Fungal Infections, ed by B Elewski, p 106, Igaku-Shoin Inc, New York, 1992..

  • 14

    Trépanier EF, Amsden GW: Current issues in onychomycosis. .Ann Pharmacother 32::204. ,1998. .

  • 15

    Del Rosso JQ: Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. .J Am Osteopath Assoc 97::339. ,1997. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Greer DL: Evolving role of nondermatophytes in onychomycosis. .Int J Dermatol 34::521. ,1995. .

  • 17

    Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. .Clin Microbiol Rev 11::415. ,1998. .

  • 18

    Weinberg JM, Koestenblatt EK: Comparison of diagnostic methods in the evaluation of onychomycosis. .Dermatol Online J [serial online]7::23G. ,2001. . Available at: http://dermatology.cdlib.org/DOJvol7num1/nails/abstracts/weinberg.html. Accessed January 24, 2003.

    • Search Google Scholar
    • Export Citation
  • 19

    Lagana FJ: Nondermatophytes: pathogen or distracter in onychomycosis. .Clin Podiatr Med Surg 12::255. ,1995. .

  • 20

    Lawry MA: Methods for diagnosing onychomycosis: a comparative study and review of the literature. .Arch Dermatol 136::1112. ,2000. .

  • 21

    Loveland LJ: Onychomycosis in HIV-positive patients. .Clin Podiatr Med Surg 15::305. ,1998. .

  • 22

    Katz HI: Systemic antifungal agents used to treat onychomycosis. .J Am Acad Dermatol 38::S48. ,1998. .

  • 23

    Katz HI: Drug interactions of the newer oral antifungal agents. .Br J Dermatol 141::26. ,1999. .

  • 24

    Katz HI: Possible drug interactions in oral treatment of onychomycosis. .JAPMA 87::571. ,1997. .

  • 25

    Katz HI, Gupta AK: Oral antifungal drug interactions. .Dermatol Clin 15::535. ,1997. .

  • 26

    Tom CM, Kane MP: Management of toenail onychomycosis. .Am J Health Syst Pharm 56::865. ,1999. .

  • 27

    Torres-Rodríguez JM, Madrenys N, Nicolás MC: Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. .Mycoses 34::499. ,1991. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Syed TA, Ahmadpour OA, Ahmad SA, et al: Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. .J Dermatol 25::648. ,1998. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Fritsch H, Stettendorf S, Hegemann L: Ultrastructural changes in onychomycosis during the treatment with bifonazole/urea ointment. .Dermatology 185::32. ,1992. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Bonifaz A, Ibarra G: Onychomycosis in children: treatment with bifonazole-urea. .Pediatr Dermatol 17::310. ,2000. .

  • 31

    Bonifaz A, Guzmán A, Garcia C, et al: Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. .Int J Dermatol 34::500. ,1995. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Roberts DT, Hay RJ, Doherty VR, et al: Topical treatment of onychomycosis using bifonazole 1% urea/40% paste. .Ann N Y Acad Sci 544::586. ,1988. .

  • 33

    Hay RJ, Roberts DT, Doherty VR, et al: The topical treatment of onychomycosis using a new combined urea/imidazole preparation. .Clin Exp Dermatol 13::164. ,1988. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Niewerth M, Korting HC: Management of onychomycoses. .Drugs 58::283. ,1999. .

  • 35

    Stettendorf S: “Topical Treatment of Onychomycosis with Bifonazole-Urea Ointment,” in Onychomycosis, ed by S Notting, HC Korting, p 102, Springer, Berlin, 1990..

    • Crossref
    • Export Citation
  • 36

    Bohn M, Kraemer KT: Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. .J Am Acad Dermatol 43: (suppl 4):S57. ,2000. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Penlac Nail Lacquer [product monograph], Dermik Laboratories Inc, Berwyn, PA, 2000..

  • 38

    Markus A: “Hydroxy-pyridones: Outstanding Biological Properties,” in Hydroxy-pyridones as Antifungal Agents with Special Emphasis on Onychomycosis, ed by S Shuster, p 3, Springer-Verlag, Berlin, 1999..

    • Crossref
    • Export Citation
  • 39

    Dittmar W, Lohaus G: HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. .Arzneim-Forsch 23::670. ,1973. .

  • 40

    Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. .J Am Acad Dermatol 43::S70. ,2000. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41

    Penlac Nail Lacquer [package insert], Dermik Laboratories Inc, Collegeville, PA, 2000..

  • 42

    Haria M, Bryson HM: Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. .Drugs 49::103. ,1995. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43

    Zaug M, Bergstraesser M: Amorolfine in the treatment of onychomycoses and dermatomycoses. .Clin Exp Dermatol 17::61. ,1992. .

  • 44

    Wadhams PS, Griffith J, Nikravesh P, et al: Efficacy of a surfactant, allantoin, and benzalkonium chloride solution for onychomycosis: preliminary results of treatment with periodic debridement. .JAPMA 89::124. ,1999. .

    • Search Google Scholar
    • Export Citation
  • 45

    Fungoid Tincture information. Available at: http://www.pedinol.com. Accessed August 14, 2001..

  • 46

    Mycocide NS product information. Available at: http://www.woodwardlabs.com. Accessed August 15, 2001..

  • 47

    PlanetRx information. Available at: http://planetrx.com. Accessed July 25, 2000..

  • 48

    Physician’s Desk Reference, Medical Economics Co, Inc, Montvale, NJ, 2000..

  • 49

    Buck DS, Nidorf DM, Addino JG: Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. .J Fam Pract 38::601. ,1994. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50

    Meyerson MS, Scher RK, Hochman LG, et al: Open-label study of the safety and efficacy of Fungoid® Tincture in patients with distal subungual onychomycosis of the toes. .Cutis 49::359. ,1992. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51

    Montana JB, Scher RK: A double-blind, vehicle-controlled study of the safety and efficacy of Fungoid Tincture® in patients with distal subungual onychomycosis of the toes. .Cutis 53::313. ,1994. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52

    Maruzella JC, Liguori L: The in vitro antifungal activity of essential oils. .J Am Pharm Assoc 47::250. ,1958. .

  • 53

    Tosti A, Piraccini BM, Stinchi C, et al: Relapses of onychomycosis after successful treatment with systemic antifungals: a three year follow-up. .Dermatology 197::162. ,1998. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54

    Gupta AK, Baran R: Ciclopirox nail lacquer solution 8% in the 21st century. .J Am Acad Dermatol 43::S96. ,2000. .

Topical Treatments for Onychomycosis

A Historical Perspective

Myron A. Bodman Cleveland Foot and Ankle Clinic, Ohio College of Podiatric Medicine, Cleveland.

Search for other papers by Myron A. Bodman in
Current site
Google Scholar
PubMed
Close
 DPM
,
Lisa Feder Scientific Connexions, Newtown, PA.

Search for other papers by Lisa Feder in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Angela M. Nace Scientific Connexions, Newtown, PA.

Search for other papers by Angela M. Nace in
Current site
Google Scholar
PubMed
Close
 PharmD
Restricted access

Topical treatment of onychomycosis, in contrast to systemic oral therapy, allows the patient to apply medication directly to the affected area, thereby decreasing the potential for adverse events and drug interactions. Historically, several topical antifungal agents have been used in the treatment of onychomycosis; however, the evidence for their effectiveness is based on very limited data or anecdotal reports. Recently, the development of new, effective topical agents has renewed interest in this form of therapy. As clinical experience with newer topical agents expands, they may be found to be an effective option for the treatment of onychomycosis. (J Am Podiatr Med Assoc 93(2): 136-141, 2003)

Corresponding author: Myron A. Bodman, DPM, Cleveland Foot and Ankle Clinic, Ohio College of Podiatric Medicine, 10515 Carnegie Ave, Cleveland, OH 44106.

This article was supported by an unrestricted educational grant from Dermik Laboratories, Berwyn, Pennsylvania. Drs. Feder and Nace both received funding from Dermik Laboratories. Dr. Bodman has received monetary compensation for speaking engagements from Dermik Laboratories.